Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
RegulatoryapprovedJaypircaPositive
AI Analysis
Summary
The FDA approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, for certain patients with previously untreated CLL/SLL, broadening its approved use.
Outcome Details
FDA approved expanded indication for Jaypirca for certain patients with previously untreated CLL/SLL
Importance:8/10
Sentiment:
0.85
FDA approvallabel expansionBTK inhibitorCLL/SLLEli Lilly
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 2, 2026 7:05 PM